

Table S1. Demographics, previous and ongoing treatments, and visual acuity in Birdshot chorioretinitis with different activity outcomes.

	ACTIVE- INACTIVE		<i>p</i> -value	ACTIVE- ACTIVE		<i>p</i> -value	INACTIVE- INACTIVE		<i>p</i> -value
	n	%		n	%		n	%	
Patients	13	43.3		12	40.0		18	60.0	
Eyes	16	26.7		17	28.3		27	45.0	
Laterality: Right Eye	6	37.50	0.262	7	41.18	0.410	17	62.96	0.078
Previous Treatments	n	%		n	%		n	%	
PPV	1	6.25	0.991	1	5.88	0.936	2	7.41	0.848
DEX	9	56.25	0.032	5	29.41	0.708	6	22.22	0.109
Cumulated PDN (mg)	1188.75	1269.51	1.000	2011.77	2940.32	0.032	670.00	711.38	0.051
	mean	±SD		mean	±SD		mean	±SD	
Time IMT/Evol (m)	0.26	0.27	0.469	0.35	0.38	0.706	0.33	0.42	0.763
Time BIO/Evol (m)	0.27	0.29	0.955	0.29	0.32	0.675	0.25	0.32	0.667
Time IMT or BIO/Evol	0.53	0.39	0.535	0.64	0.39	0.505	0.58	0.43	0.958
Ongoing Treatments	n	%		n	%		n	%	
BL DEX	2	12.50	0.187	0	0.00	0.361	1	3.70	0.735
12 m DEX	4	25.00	0.042	2	11.77	0.767	0	0.00	0.022
Δ 12 m - BL	2	13	0.304	2	12	0.334	-1	-4	0.073
BL Systemic CS	6	37.50	0.205	7	41.18	0.089	2	7.41	0.005
12 m Systemic CS	5	31.25	0.761	9	52.94	0.013	3	11.11	0.008
Δ 12 m - BL	-1	-6	0.187	2	12	0.152	1	4	0.289
BL Classic IMT	3	18.75	0.225	2	11.77	0.767	1	3.70	0.172
12 m Classic IMT	3	18.75	0.482	2	11.77	0.866	3	11.11	0.676
Δ 12 m - BL	0	0	0.698	0	0	0.767	2	7	0.298
BL Biotherapy	3	18.75	0.433	7	41.18	0.133	6	22.22	0.502
12 m Biotherapy	5	31.25	0.623	9	52.94	0.117	8	29.63	0.324
Δ 12 m - BL	2	13	0.698	2	12	0.767	2	7	0.698
Lens Status	n	%		n	%		n	%	
BL Cataract	2	12.50	0.649	4	23.52	0.398	4	14.81	0.749
12 m Cataract	2	12.50	0.147	7	41.18	0.133	7	25.93	0.914
Δ 12 m - BL	0	0	0.949	3	18	0.717	3	11	0.550
BL Clear	10	62.50	0.826	11	64.71	0.659	15	55.56	0.539
12 m Clear	10	62.50	0.262	8	47.06	0.784	12	44.44	0.452
Δ 12 m - BL	0	0	0.949	-3	-18	0.401	-3	-11	0.918
BCVA (LogMAR)	mean	±SD		mean	±SD		mean	±SD	
BL BCVA	0.42	0.72	0.383	0.29	0.35	0.748	0.29	0.41	0.627
12 m BCVA	0.34	0.51	0.750	0.25	0.30	0.566	0.32	0.57	0.813
Δ 12 m - BL	-0.08	0.28	0.199	-0.04	0.12	0.591	0.03	0.21	0.103

The *p*-value indicates the deviation from the entire population in the characterization of the A-I, A-A, and I-I groups with the respective characterizing variables. Lighter shades of grey signify a decrease, while darker shades denote an increase from baseline to 12 months of follow-up. *p* < 0.05 is marked in bold. Abbreviations: BL: baseline; m: months; PPV: pars plana vitrectomy; DEX: intravitreal Dexamethasone implant; PDN: prednisone; IMT: classic synthetic immunomodulatory therapy; BIO: biotherapy; BCVA: best correct visual acuity.